{"id":5163,"date":"2026-10-16T10:49:59","date_gmt":"2026-10-16T10:49:59","guid":{"rendered":"https:\/\/nhdbio.com\/?p=5163"},"modified":"2026-10-16T10:49:59","modified_gmt":"2026-10-16T10:49:59","slug":"semaglutide-step1-extension-weight-regain-explained","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/semaglutide-step1-extension-weight-regain-explained\/","title":{"rendered":"\u0628\u0639\u062f \u0627\u0644\u0627\u0646\u0633\u062d\u0627\u0628 \u0645\u0646 \u0627\u0644\u0633\u064a\u0645\u0627\u063a\u0644\u0648\u062a\u064a\u062f: \u0642\u0631\u0627\u0621\u0629 \u0645\u062a\u0627\u0628\u0639\u0629 STEP 1"},"content":{"rendered":"
\n

After Semaglutide Withdrawal: Reading the STEP 1 Follow-up<\/h2>\n

Read the STEP 1 extension's weight changes with the follow-up population, baseline and stopped interventions clearly identified.<\/p>\n

\"After
\u0631\u0633\u0645 \u062a\u0648\u0636\u064a\u062d\u064a \u062a\u062d\u0631\u064a\u0631\u064a\u060c \u0648\u0644\u064a\u0633 \u0635\u0648\u0631\u0629 \u062a\u062c\u0631\u064a\u0628\u064a\u0629.<\/figcaption><\/figure>\n

The extension did not include everyone randomized<\/h3>\n

STEP 1 initially randomized 1961 adults with overweight or obesity and without diabetes. Extension analyses included 327 participants from selected eligible sites and participants. The extension was exploratory; its results do not represent complete follow-up of every person initially randomized.<\/p>\n

Put the three timepoints on one baseline<\/h3>\n

In the extension population, mean weight change from week 0 to week 68 was \u221217.3% with semaglutide and \u22122.0% with placebo. At week 120, changes from the original baseline were \u22125.6% and \u22120.1%. The figure joins these three summaries, not daily measurements or individual trajectories.<\/p>\n

\"STEP
Exploratory follow-up, n=327. Drug and lifestyle intervention stopped at week 68. Lines join three summary timepoints, not continuous measurements. Group means are shown.<\/figcaption><\/figure>\n
\n\n\n\n\n\n\n\n
STEP 1 extension: body-weight change<\/caption>\n
Weeks<\/th>\n\u0633\u064a\u0645\u0627\u062c\u0644\u0648\u062a\u064a\u062f<\/th>\n\u062f\u0648\u0627\u0621 \u0648\u0647\u0645\u064a<\/th>\n<\/tr>\n<\/thead>\n
0<\/th>\n0%<\/td>\n0%<\/td>\n<\/tr>\n
68<\/th>\n\u221217.3%<\/td>\n\u22122.0%<\/td>\n<\/tr>\n
120<\/th>\n\u22125.6%<\/td>\n\u22120.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

More than medication stopped<\/h3>\n

At week 68, trial treatment and the lifestyle intervention both stopped. This was not a situation where only medication changed and every other support remained identical. The paper reports subsequent regain of 11.6 percentage points in the semaglutide group. Preserve reported values: rounding can prevent exact subtraction of separate summaries.<\/p>\n

Percentages need their stated denominator<\/h3>\n

Moving from \u221217.3% to \u22125.6% describes changes relative to the original body-weight baseline. It does not mean every participant gained 17.3%, or provide a new percentage using week 68 weight as the denominator. Changing the denominator changes the question.<\/p>\n

What the graph cannot predict<\/h3>\n

Group means cannot predict an individual's course or provide a personal stopping plan. The clinical formulation, participant characteristics and follow-up arrangements differ from catalog-material information. Interpretation needs the complete trial context, not one isolated weight-regain figure.<\/p>\n

The related catalog item is a different material<\/h3>\n

The website lists Cagrilintide + Semaglutide Blend, a combined material rather than the single-agent semaglutide formulation studied in STEP 1. Its card is a catalog enquiry route, not an application of the single-agent trial results to the blend. Composition, form and batch information require separate confirmation.<\/p>\n

\u0645\u0631\u0627\u062c\u0639<\/h3>\n